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1. Introduction 
In current drug development, proof-of-concept—determining whether a ligand engaging its 
target is likely to be therapeutic—requires specific ligands. This presents a catch-22, as the 
motivation to develop ligands requires proof-of-concept studies that cannot be conducted 
without ligands. A strategy we term genetic pharmacotherapy—a refinement of genetic 
blockade focused on druggable targets—obviates the catch-22 by enabling proof-of-concept 
studies prior to the development of specific ligands via genetic means in mouse models. In 
this strategy, which could help avert investment in molecular entities that will ultimately 
prove therapeutically inefficacious, a gene is conditionally down-regulated via a molecular 
switch in adult mice. Both the precise temporal control of the intervention and the 
consequent change in target protein function parallel the administration of drugs, with the 
additional advantage of perfect specificity. Moreover genetic pharmacotherapy overcomes 
the impediment of the blood-brain barrier, which makes developing ligands for psychiatric 
disorders particularly challenging. Here, we describe the transgenic technologies that form 
the basis for the strategy, discuss the advantages and limitations in juxtaposition with other 
gene expression modification approaches, contrast examples of prior implementation, 
address the feasibility for systematic use, and illustrate past and future opportunities. 
Although the molecular tools are widely available, genetic pharmacotherapy has only been 
implemented outside the central nervous system (CNS), despite its particular utility for CNS 
disorders. The systematic application of this strategy should foster the development of new, 
innovative molecular therapies. 
2. The conceptual basis and requisite components of genetic 
pharmacotherapy 
We define genetic pharmacotherapy as the use of a genetic intervention to achieve a 
pharmacological effect. Genetic pharmacotherapy has two requirements. First, genetic 
blockade must be universal — reaching all cells in the body, including the brain — to 
simulate organism-wide drug distribution. Second, induction of gene-modulation must be 
temporally controllable, as opposed to originating during embryogenesis, so that target 
modulation occurs as it would with drug administration. While traditional knockout 
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strategies have been used extensively to study the roles of proteins in a broad range of 
disorders, constitutive mutations are often lethal in early life precluding study of target gene 
function in adulthood (Lewandoski, 2001). Moreover, many non-lethal knockouts of genes 
of interest elicit paradoxical phenotypes — phenotypes that are opposite to the effects of 
pharmacologic blockade of the same target in adulthood — as a result of developmental 
compensations (Gingrich & Hen, 2000). The genetic strategy that satisfies these two 
requirements is a refinement of Cre-lox recombination, in which two individually silent 
mutations are introduced. One mutation drives a ligand-inducible effector enzyme that 
enables target-modulation, and the other mutation makes the target gene of interest 
susceptible to inactivation by the effector enzyme. This involves breeding a mouse carrying 
the inducible effector — CreERT — with an animal carrying the effector-sensitized floxed 
gene-of-interest. In the resulting progeny, inducing the CreERT produces irreversible target 
modulation paralleling the institution of pharmacotherapy. 
2.1 Origins of the inducible-Cre strategy 
In Cre-lox recombination, Cre recombinase — from P1 bacteriophage — recognizes two 
closely spaced 34-base pair loxP sequences, excises the intervening sequence, and recombines 
the flanking strands. When placed strategically by homologous recombination, the excision 
inactivates the so-called floxed gene (Nagy, 2000; Sternberg & Hamilton, 1981) (Figure 1a). To 
inactivate the target gene, a mouse that carries the Cre transgene is bred with a mouse carrying 
loxP sites flanking a portion of the gene of interest (the floxed gene); in the resulting F1 






Fig. 1. Removal of targeted DNA sequences by Cre-lox recombination. A. Cre recombinase 
excises the portion of DNA between the loxP recognition sites (the floxed gene), 
recombining the flanking strands. B. To accomplish this in mice, a mouse carrying the Cre 
transgene is bred with a mouse carrying the floxed gene (F0 generation). In the progeny (F1), 
the floxed gene will be recombined in all Cre-expressing cells. If Cre is driven by a cell-
specific promoter, recombination will be restricted to just those cells; if Cre is driven by a 
universally-expressed promoter, recombination will be universal. 
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In 1992, two groups (Lakso et al., 1992; Orban et al., 1992) reported the first use of Cre in 
mice to achieve tissue-specific expression. In 1994, Rajewsky and colleagues (Gu et al., 1994) 
employed Cre as a conditional gene-targeting tool to circumvent the pleiotropic embryonic 
lethality of the same null mutation. Tissue-specific Cre-mediated conditional gene 
inactivation has enabled investigators to address questions that would be otherwise 
intractable in global knockouts (Lewandoski, 2001). However, as mentioned, to best 
simulate treatment with a drug, which permeates the entire body, inactivation of the target 
gene should take place in every tissue type — and thus Cre expression should be driven by 
a universally-expressed promoter such as the hybrid chicken beta-actin promoter and 
cytomegalovirus enhancer (CAG) promoter. This promoter was dramatically shown to drive 
expression of enhanced green fluorescent protein (EGFP) in virtually every cell type to 
produce green mice (Okabe et al., 1997) (Figure 2). 
 
 
Fig. 2. The transgenic CAG promoter drives expression universally. Five mouse pups are 
seen under normal light (left); under blue light excitation (right), two of the pups fluoresce 
green as a result of expression of the ubiquitous CAG promoter that drives EGFP expression 
in all cell types (in the mice, only red blood cells and hair are not green) (From: Okabe et al., 
1997, with permission). 
2.1 Modified, ligand-activated CreERT enables temporal control over target gene 
modulation 
To achieve temporal control of Cre recombination, Chambon and colleagues (Feil et al., 
1996; Metzger & Chambon, 2001; Metzger et al., 1995) created a ligand-dependent version of 
Cre, the chimeric protein CreERT, which mediates recombination only in the presence of the 
drug tamoxifen or its derivatives. In CreERT, Cre is fused to the mutated ligand-binding 
domain of the estrogen receptor, which recognizes tamoxifen and 4OH-tamoxifen, but not 
endogenous estrogen (Figure 3a). As a steroid receptor of the nuclear receptor family, the 
estrogen receptor in its inactive form is restricted to the cytoplasm via association with 
chaperone proteins (Giguère, 2003). As with estrogen activation of the native steroid 
receptor, tamoxifen releases CreERT from chaperone proteins, enabling the recombinase to 
diffuse into the nucleus to mediate site-specific recombination (Figure 3b). Consequently, 
target gene-inactivation is temporally controlled and tamoxifen-dependent, as CreERT 
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remains in the cytoplasm until tamoxifen-administration, and returns to the cytoplasm once 
tamoxifen is no longer in the system. 
 
 
Fig. 3. Temporally controlled, ligand-dependent Cre-lox recombination. A. A mutated 
version (Gly521Arg) of the estrogen receptor ligand binding domain (LBD) that 
recognizes tamoxifen but not estrogen was fused to the Cre protein, resulting in the chimeric 
protein CreERT (From Metzger & Chambon, 2001, with permission). B. In the absence of 
tamoxifen or derivatives, the location of CreERT is restricted to the cytoplasm by association 
with chaperone proteins (i). When engaged by its high-affinity, high-specificity ligand 
tamoxifen, CreERT is released from the chaperone proteins and diffuses into the nucleus (ii), 
only then allowing Cre access to recombine genomic DNA irreversibly (iii & iv). After 
tamoxifen clearance, CreERT will again become sequestered in the cytoplasm (iv). 
An enhanced version, CreERT2, is now generally used as it has about a 4-fold greater 
induction efficiency over CreERT (Indra et al., 1999; Lewandoski, 2001 citations 112-115). For 
some transgene combinations, there may be some recombination in the absence of tamoxifen 
(Figure 4) (Hayashi, 2002), so evaluation of the magnitude of pre-tamoxifen recombination 
will therefore be a necessary control. Several ubiquitous inducible Cre lines are available 
(Table 1). An alternate strategy employs a modified progesterone receptor that is activated 
by RU486 (Kellendonk et al., 1999). 
 
Cre line Strain name Stock Number 
CagCreERT1 B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J 004682 
RosaCreERT2 B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J 008463 
UBC-CreERT2 B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J 008085 
Table 1. Ubiquitously expressed inducible Cre lines. Mice are readily available 
(jaxmice.jax.org). 
Until recently, mice with floxed alleles were generated in individual laboratories and the 
range of commercially available lines of mice with floxed alleles was limited. Now, floxed 
mice are being made systematically through a multinational consortium, the Knockout 
Mouse Project (www.komp.org) (Skarnes et al., 2011). The goal of KOMP is to produce 
conditional alleles of all expressed mouse genes. So far, 9,000 floxed alleles are or will soon 
be available, and floxed alleles for the remainder of mouse genes should be accessible in the 
near term. This comprehensive resource provides the basis for systematic target evaluation 
using genetic pharmacotherapy. 
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Fig. 4. CreERT2-mediated recombination prior to tamoxifen induction. In a small percentage 
of cells, recombination occurs in (A) cerebral cortex, (B) cerebellum, (C) heart, (D) kidney, 
(E) lung, and (F) liver in the absence of tamoxifen (left-most column), as shown by β-
galactosidase expression, with the CagCreERT2 mouse line. After tamoxifen (doses shown 
on top) there is a massive induction of expression (From: Hayashi, 2002, with permission). 
3. Comparability to target-specific drugs, with advantages and limitations  
Using inducible Cre-lox recombination to inhibit target gene expression offers comparability 
to, as well as many advantages over, ligand-based inhibition for proof-of-concept studies. 
Comparable to pharmacologic treatment, genetic pharmacotherapy enables control over the 
degree of target modulation, analogous to adjustments in drug dose, to assess dose-
response; and it also mimics the global, organism-wide action of drug intervention, which 
enables assessment of possible side effects due to pleiotropic target expression. The 
strategy’s advantages include preclusion of off-target effects via perfect target-specificity, 
and access to targets in the CNS via permeation of the blood-brain-barrier, which stymies 
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the evaluation of many drug candidates for CNS disorders. There are limitations; these 
include relative difficulty in targeting splice variants (protein isoforms from the same gene), 
as the strategy works at the DNA level, and an inability to capture the subtleties of drug 
action at targets that exhibit functional heterogeneity, i.e. differential structural 
conformations, drug affinities, and function of a single gene product. We examine each of 
these points in further illustration below. 
3.1 Relative change induced in target-protein function is commensurate to agonism 
and antagonism 
Often, in order to evoke a response in the host cell system, a drug need occupy only a 
fraction of the total receptors available—a function of both the drug’s affinity and the 
intrinsic ability of the drug-receptor interaction to induce cellular change. This causes the 
dose-response curve to shift to the left of the receptor occupancy curve, so that a drug dose 
that elicits maximal tissue response may cause only partial occupation of the available 
receptors (Figure 5). 
  
 
Fig. 5. Maximal tissue response at sub-maximal receptor occupancy. Based on efficacy, drug 
doses generally need to activate only a fraction of the total available receptors to induce a 
maximal tissue response. In this illustration, the drug dose that induces maximal tissue 
response (red line) activates only a fraction of the total available receptors. (Modified from: 
Ross & Kenakin, 2001, with permission from the McGraw-Hill Companies, Inc.) 
For example, opiate agonists etorphine and sufentanil have significant analgesic activity at 
very low receptor occupancy — approximately 2% at the ED50 (Rosenbaum et al., 1984); and 
in another example, only 22% receptor occupancy is needed for half-maximal stimulation by 
PEG-TPOm, a mimetic peptide agonist in development for protection against 
chemotherapy-induced thrombocytopenia (loss of blood platelets) (Samtani et al., 2009). The 
antipsychotic dopamine D2 receptor antagonist olanzapine achieves optimal clinical efficacy 
at about 60% receptor occupancy (Mamo et al., 2007).  
Similarly, genetic pharmacotherapy need not produce full target inhibition in order to elicit 
a response. Quantitative gradation in target protein expression (in analogy to a drug dose 
range) can be controlled by floxing one or both alleles of the gene of interest, and by 
tamoxifen dose (Figure 6) and frequency of administration; in adult mice, tamoxifen is 
generally administered once daily for 5 days to achieve full recombination. Varying 
tamoxifen dosing can then mimic the range of drug action. 
www.intechopen.com
 Genetic Pharmacotherapy 131 
While the Cre-lox strategy can also be used to simulate agonism, as discussed in later 
sections, we focus mainly on its application to simulate target antagonism, as the majority of 
drugs are inhibitors (Copeland et al., 2007; Li et al., 2007) and the accessibility of both 
ubiquitous CreERT2 mice and the floxed target of choice should now enable systematic in 
vivo target evaluation. 
 
 
Fig. 6. Tamoxifen dose-dependent recombination in embryos with CreERT driven by a 
universally expressed promoter. Although Cre-mediated gene modulation is irreversible, 
“dosing” as a percentage of cells undergoing recombination can still be controlled. Whole-
mount transgenic embryos were assayed 9.5 days post-coitum for activity of target gene, β-
galactosidase, whose expression had been induced by tamoxifen at the indicated doses (per 
40 kg mouse weight) 24 hours prior via intraperitoneal injection of the pregnant dam. (From: 
Hayashi, 2002, with permission). 
To evaluate potential therapeutic efficacy of target modulation, biomarkers or surrogate 
endpoints specific to the disease model can be used as a response measure—for example, 
the lowering of blood glucose for genetic pharmacotherapy interventions in diabetes 
models, LDL cholesterol levels in dyslipidemia models, or PET imaging of ligand binding in 
CNS models. 
3.2 Ubiquitously expressed effector simulates organism-wide pharmacologic actions 
In this gene expression modulation system, the effector protein CreERT2 controls the 
expression of the target gene (for the candidate drug target). In order to achieve the closest 
simulation of a pharmacologic agent, which has organism-wide effects, it is paramount that 
a ubiquitously expressed locus such as Rosa26 (Soriano, 1999; Ventura et al., 2007) be used 
to drive the effector protein expression (Table 1). This way it is possible to assess the 
phenotypic consequences of pleiotropy occurring in targets — that is, the side effects arising 
from inhibiting a gene product that participates in multiple signaling or metabolic pathways 
or in different tissues (for further discussion of the relevance of pleiotropies to 
pharmacotherapy, see Hodgkin, 1998; Searls, 2003). While small interfering RNA (siRNA) 
has been used extensively for controlled gene inhibition in proof-of-concept studies, siRNA 
is not drug-like, as it must be delivered to the tissue of interest (Davidson & McCray, 2011). 
3.3 Superiority over pharmacologics: preclusion of off-target effects via perfect 
target-specificity 
Since Paul Ehrlich, drug design has aspired to the ideal of “magic bullet” drugs that seek out 
only “enemy targets” involved in pathology while leaving the body unharmed 
(Parascandola, 1981). Lack of target specificity not only severely limits the use of small 
molecules as therapeutics — for example, the clinical use of anti-Parkinsonian drugs 
pergolide and cabergoline has been greatly limited because their off-target effects cause 
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valvular heart disease (Keiser et al., 2009) — but also restricts their use as experimental tools 
in proof-of-concept evaluation (Peterson, 2008). Although promiscuous targeting and multi-
receptor activity do produce therapeutic benefits when single-receptor action does not — for 
example, in the case of statins and psychotropic medications (Keiser et al., 2009; Peterson, 
2008) — it is nonetheless preferable that well-defined functional outcomes be understood 
through well-delineated biochemical actions. Even a drug with high specificity that achieves 
a desirable outcome in an animal model or clinically still cannot be concluded to work only 
via the pathway assumed. Genetic pharmacotherapy, on the other hand, enables 
demonstration of precise, controlled causality in in vivo studies. 
This is not to say that benefits of polypharmacy cannot be addressed with genetic 
pharmacotherapy; indeed, the synergy of inhibiting multiple targets simultaneously could 
be assessed in mice with multiple floxed alleles or by combining genetic pharmacotherapy 
with traditional pharmacotherapy. It may be impractical to translate findings from such an 
experiment into a ligand that accomplishes the same synergistic inhibition, but it would 
enable investigators to parse precisely which targets mediate the desired results, and could 
guide drug optimization efforts. 
Along these lines, genetic pharmacotherapy raises the possibility of validating previously 
established targets. For example, every antipsychotic drug approved so far has dopamine 
D2 receptor-blocking activity based on the presumed mode of action of first-generation 
antipsychotics, which was an entirely serendipitous discovery. However, it likely that their 
therapeutic efficacy involves interaction with other targets; for instance, antipsychotics 
inhibit KCNH2, a recently described potassium channel, found to be overexpressed in the 
brains of patients with schizophrenia (Huffaker et al., 2009). The authors state: 
“Whereas D2 receptor affinity is thought to account for the therapeutic effects of
antipsychotics, KCNH2 binding is responsible at least for side effects such as altered
QT interval or even sudden cardiac failure. Given that KCNH2 controls neuronal
excitability and firing patterns, could the therapeutic effects of antipsychotic drugs
also be related to their affinities for the brain-specific isoforms of KCNH2? 
(Huffaker et al., 2009)” 
With the present lack of specific KCNH2 ligands, genetic pharmacotherapy could enable 
further dissection of this possibility and resolve the conceptual justifications guiding the 
development of compounds with similarly intended actions, pharmacologic or therapeutic. 
3.4 Specific advantages with regard to CNS targets 
Genetic pharmacotherapy offers particular advantages for proof-of-concept studies for CNS 
disorders. Such studies face not only the obstacle of designing high-affinity, high-specificity 
ligands, as in evaluation of targets in other tissues, but also the blood-brain barrier — the 
superfine filter composed of endothelial cells lining brain capillaries and astrocytes — that 
either blocks or actively transports out more than 98% of candidate drugs (Miller, 2002). 
Genetic pharmacotherapy circumvents this obstacle because tamoxifen permeates the blood-
brain barrier freely. 
3.5 Limitations of achieving target inhibition via DNA modification 
While drugs can distinguish between different protein isoforms arising from RNA splice 
variants (Thompson et al., 2011) that may have different anatomical and functional 
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specificities (Huffaker et al., 2009), genetic pharmacotherapy cannot make such a distinction 
easily, as target inhibition is mediated via changes at the DNA level. Similarly, a drug may 
interact differentially with receptors exhibiting functional heterogeneity — e.g. a receptor 
with distinct allosteric conformations and signaling complexes, varying by anatomical 
distribution (Mailman, 2007; Mailman & Murthy, 2010) — a subtlety less amenable to 
simulation with genetic pharmacotherapy but achievable in some cases with pharmacology. 
The D2 dopamine receptor provides a classic example: agonist stimulation of presynaptic 
D2 dopamine autoreceptors diminishes dopamine synthesis and release, which may achieve 
a dopamine antagonist-like effect post-synaptically via decreased dopamine 
neurotransmission -- whereas preferential agonism of post-synaptic D2 dopamine receptors 
would achieve the opposite effect. Selective targeting of distinct cell-type D2 receptors 
cannot be achieved with a universal CreERT line, but the D2 receptor partial agonist 
aripiprazole appears to exhibit such functional selectivity. Nevertheless, a judiciously 
chosen tissue-specific inducible CreERT2 strategy may allow such issues to be addressed 
with better precision than with pharmacology. For instance, presynaptic dopamine D2 
receptors have been selectively targeted using a DAT-Cre driver (Bello et al., 2011), and 
DAT-CreERT2 mice have been reported (Engblom et al., 2008), so that such changes could 
be induced in adulthood to model an autoreceptor selective dopamine D2 receptor 
antagonist. 
4. Evolution of genetic pharmacotherapy 
Genetic pharmacotherapy builds on molecular developments of the last two decades. Below 
we describe seminal applications of aspects of the genetic pharmacotherapy strategy, and, in 
certain instances, the molecular entities with actions mirroring the corresponding genetic 
intervention. Where we wish to build on these foundations is in illustrating the feasibility 
and advantages of applying this concept — specifically, by employing inducible Cre-lox 
technology — to evaluate new potential therapeutic drug targets systematically, particularly 
in the CNS, a possibility that has not yet been articulated until now. 
4.1 Genetic blockade in lieu or absence of pharmacologic blockade 
The potential advantages of using genetic blockade in place of a pharmacologic blockade for 
CNS studies were described in 1996 in studies reporting the first transgenic expression of 
Cre in the mouse nervous system (Tsien et al., 1996): 
“Studies of … mechanisms underlying … vertebrate animal [behavior] have
traditionally been carried out using pharmacological blockades…. gene knockouts
provide an alternative means. While the two methods are complementary, genetic
deletion is generally superior to pharmacological blockade with respect to molecular
and anatomical specificities and animal-to-animal reproducibility. For instance, while
many antagonists cannot distinguish receptor isoforms, genetic blockade can make
that distinction. Likewise… a genetic blockade can be highly confined and
reproducible.” 
The juxtaposition of genetic and pharmacologic blockade, in this instance, pertains to their 
relative merits as experimental tools for addressing questions regarding memory formation 
as opposed to new therapeutic targets. In a related, concurrent study, the tetracycline 
transactivator system (described below) was used for regional and temporal control over 
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calcium-calmodulin-dependent kinase II (CamKII) expression to demonstrate the 
requirement of CamKII for both implicit and explicit memory formation (Mayford et al., 
1996). 
4.1.1 Tetracycline-regulatable gene expression 
The tetracycline transactivator system (Gossen & Bujard, 1992) offers another ligand-
controlled gene expression system, in which the targeted gene is turned off or on by the 
administration of tetracycline or (more commonly) doxycycline (Figure 7a). In this system, 
the E. coli-derived tetracycline-controlled transactivator (tTA) drives target-gene 
transcription by binding to a modified tet operator (tetO) sequence, and this activity can be 
diminished and switched off depending on varying concentrations of doxycycline. This 
strategy is adapted from the E. coli tetracycline-resistance operon, in which transcription of 
tetracycline resistance-mediating genes is negatively regulated by the tetracycline repressor 
(tetR). The presence of tetracycline causes the dissociation of tetR from the promoter region 
of the operon and enables transcription of resistance genes. In contrast, as just mentioned, 
the modified transactivator tTA, based on tetR, stimulates (as opposed to repressing) 
transcription when bound to minimal promoters fused to tetO sequences, and the presence 
of low concentrations of tetracycline (<100 nM) or doxycycline prevents the binding of tTA 
to the tetO sequences and thereby halts transcription. In the modified tet-on version of this 
system (Kistner et al., 1996), doxycycline turns on target gene expression via a reverse tTA 
(rtTA). In this case, rtTA will bind tetO to activate transcription only in the presence of 
doxycycline (Figure 7b). 
 
   
Fig. 7. Tetracycline transactivator (tTA)-controlled gene expression. (a) In tet-off gene 
regulation, the effector protein tTA binds to the tetO promoter, which activates transcription 
of the target gene. Upon the administration of doxycycline, tTA changes conformation and 
ceases to activate the target gene’s transcription. (b) In the tet-on system, a modified reverse 
tTA (rtTA) binds tetO only in the presence of doxycycline.  
While the tet-regulatable strategy is appealing for the reversibility of target modulation 
(with the addition or removal of doxycycline administration) in inhibition studies, it is 
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impossible to produce a silent mutation in the target gene, such as the introduction of loxP 
sites. In order to control the gene of interest, the tetO promoter must be substituted for the 
native promoter on one allele of the target gene, and the native promoter on the other allele, 
in turn, used to drive tTA. A study employed this strategy (Figure 8) to examine the role of 
the dopamine transporter (DAT) in scaling learning (Cagniard et al., 2006). 
In this tandem design, tissue specificity of target gene expression is maintained, but pre-
doxycycline expression levels vary considerably; this is problematic for genetic 
pharmacotherapy because target gene function should be at basal levels prior to induction. 
In the strategy illustrated in Figure 8, the mutant mice expressed modestly reduced levels of 
DAT, and it took several weeks of doxycycline administration to achieve significant 
suppression of DAT expression (Cagniard et al., 2006). In another study examining the role 
of potassium SK3 channels, SK3 expression was several fold higher than control, and was 
suppressed with doxycycline (Bond et al., 2000). 
 
 
Fig. 8. Target inhibition with tet-off system. For doxycycline-induced knockdown of the 
targeted dopamine transporter (DAT) function, tTA is expressed under the control of the 
DAT promoter pDAT on one allele, abrogating DAT expression at that locus; endogenous 
DAT expression at the other allele is also disrupted by placement of the tetO promoter 
ahead of the gene—but in cells with endogenous pDAT promoter activity driving tTA 
expression, DAT will be expressed via the tetO promoter. Thus tissue specificity of target 
expression is maintained. Doxycycline then blocks tTA action and so inhibits all DAT 
expression. 
Though less ideal for systematic target evaluation when compared to CreERT2, the 
tetracycline-transactivator system has nevertheless been particularly powerful in modeling a 
disease state and subsequently assaying the proof-of-concept of its reversibility via 
doxycycline administration. In a landmark paper, Yamamoto and colleagues (2000) created 
a mouse model of Huntington’s disease (HD) by tetO-driven, striatum-restricted expression 
of a pathogenic version of the Huntingtin protein. By 4 weeks of age, the mice began to 
exhibit choreic movements and dystonia, and by 8 weeks showed striatal Huntingtin 
aggregates — both hallmarks of HD. HD is progressive, without a specific treatment or cure, 
and prior to this study was assumed to be inexorable in its course. However, abolishing the 
expression of mutant Huntingtin by doxycycline administration in symptomatic mice not 
only halted but also reversed the accumulation of protein aggregates and progressive motor 
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decline. Although developing a pharmacologic intervention for HD has yet to be achieved, 
this study demonstrated that blocking expression of pathogenic Huntingtin in symptomatic 
subjects reversed manifestations of the disease, and indeed could be viewed as having 
achieved a cure. This proof-of-concept clearly motivates a search for drugs that would 
reverse or prevent Huntingtin protein aggregate formation. 
Kellendonk and colleagues (2006) used the tetracycline-transactivator system to address the 
possibility of reversing schizophrenia-like abnormalities induced by dopamine D2 receptor 
overexpression (D2OE) in the striatum. Imaging studies have shown that dopamine 
transmission is increased in patients with schizophrenia, involving both increased dopamine 
release and increased dopamine D2 receptor binding (Guillin et al., 2007). The D2OE mice, in 
which tTA drove striatally restricted expression of an extra human D2R allele, exhibited 
elevated receptor binding capacity — 15% higher than control littermates. The pivotal finding 
was that dopamine dysfunction — previously thought only to account for the positive 
symptoms, such as hallucinations and delusions — could be causally linked to cognitive 
deficits (Simpson et al., 2010). D2OE mice showed altered dopamine transmission in the 
prefrontal cortex as well as selective cognitive impairment in working memory tasks, a 
prefrontal cortex-dependent process, without more general cognitive deficits — similar to 
cognitive impairments in patients with schizophrenia. Administering doxycycline to reverse 
the D2OE did not reverse the working memory impairment, suggesting that the cognitive 
deficits in these mice arose not from continued D2OE but as a consequence of D2OE during 
development. Whether D2OE occurs prior to the onset of schizophrenia in patients is not 
known; however, dopamine release is increased (Howes et al., 2008), so there is clear evidence 
for increased dopamine transmission prior to the onset of schizophrenic symptoms. The earlier 
consequences of increased dopamine transmission in the D2OE mice are consistent with the 
well-recognized inability of dopamine D2 receptor antagonists to ameliorate cognitive 
impairments. It must also be noted that while genetic blockade of transgene expression 
accomplished down-regulation of D2 receptor overexpression, it did not mimic actual D2 
receptor antagonist pharmacotherapy fully, as doxycycline inhibited only the transgenic D2 
receptors while D2 antagonists would block both the transgenic as well as native D2 receptors. 
In these studies, the tetracycline-transactivator system was used to model a disease, and 
subsequently doxycycline administration was used to turn off pathogenic protein 
expression to establish causality between protein and disease. In genetic pharmacotherapy 
studies, introduction of an extra tet-regulatable allele could be used to test the effects of 
increasing target expression, mimicking the actions of a target agonist. One benefit of this 
strategy, as mentioned, is reversibility of the target modulation; however, the transgenic 
mice would need to be engineered on a per-target basis, as there is no repository analogous 
to KOMP for tet-regulatable alleles. Using the tet-off system in inhibition studies, as in the 
DAT study, disadvantageously requires engineering two transgenic mice (for both the tetO 
and tTA alleles). 
4.2 Genetic blockade techniques beyond inducible Cre and tTA 
Genetic blockade as a proof-of-concept tool has also been used in a number of oncogenic 
signaling pathway studies. Although the blockade in the following two examples was 
accomplished via methods difficult to translate to other druggable targets, the studies 
successfully established a therapeutic proof-of-concept via genetic means in the absence of a 
high-specificity ligand against the endogenous target. In one study, a silent mutation 
engineered into an oncogenic kinase allowed for its selective inhibition, whereas kinase 
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inhibitor non-specificity had previously deterred such an investigation (Fan et al., 2002). In a 
second study, tumorigenic expression of an endocrine receptor was suppressed by a 
truncated version of the same receptor (delivered via an adenovirus) that acted as a 
dominant-negative inhibitor (Min et al., 2003). In both cases, the subsequently developed 
pharmacologic inhibitors produced the same effect as the genetic blockade, corroborating 
the parallel between genetic and pharmacologic target blockade. 
4.2.1 Engineering a kinase for selective inhibition to determine its role in oncogenic 
signaling 
To overcome the lack of specific kinase inhibitors, Fan and colleagues engineered a silent 
mutation into a target kinase gene that allowed selective inhibition while retaining kinase 
activity prior to administration of the mutant kinase-specific antagonist, NaPP1 (Fan et al., 
2002). Mice subcutaneously injected with cancer cells containing endogenous or NaPP1-
sensitized versions of the epithelial growth factor receptor (EGFP) oncogene v-erbB grew 
tumors of similar size and with similar latencies — but the inhibitor NaPP1 suppressed 
growth only in tumors with the sensitized allele (Figure 9). 
 
Fig. 9. Chemical genetic blockade in a proof-of-concept study. Assay of tumor growth 
inhibition in nude mice injected with v-erbB- or v-erbB-as1-transformed cells. NaPP1 blocks 
tumor growth only in the mice with the mutagenized v-erbB-as1 allele that renders the 
kinase susceptible to selective inhibition by NaPP1 (From: Fan et al., 2002, with permission). 
Fan and colleagues (2002) concluded that selective inhibitors of EGFR may effectively arrest 
cancer cell proliferation at a favorable therapeutic index, as basal signaling in normal cells is 
unlikely to be affected. Although inhibitors selective for the ErbB EGFR were not available 
at the time of this chemical-genetic blockade study, genetically engineering inhibitor 
sensitivity demonstrated the target’s proof-of-concept. This incentivized further efforts to 
develop ligands specific for EGFR subtypes such as ErbB. Indeed, initial marketing of 
Gefitinib, an EGFR tyrosine kinase inhibitor, was approved in 2003 for patients with non-
small cell lung cancer, and Erlotinib, another EGFR tyrosine kinase inhibitor, was approved 
for the same indication in 2004 and for pancreatic cancer in 2005 (National Cancer Institute 
Online Drug Information, Pao, 2005). 
4.2.2 Virally delivered truncated IGF-I receptor as dominant-negative inhibitor of 
tumorigenesis 
Like EGFR, the insulin-like growth factor I receptor (IGF-Ir) is a mitotic growth factor that 
stimulates cell growth and is implicated in tumorigenesis (Prager et al., 1994). In certain 
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tumors, IGF-Ir appears to be essential for both malignant transformation and maintenance of 
the malignant state (Baserga, 1995; Sell et al., 1993). Additionally, initial studies indicated 
potential tumor selectivity in targeting IGF-Ir for therapeutic applications: reduction of IGF-Ir 
function induced apoptosis in tumor cells but produced only growth arrest in untransformed 
cells; and IGF-Ir knockout mice are viable, indicating it is not indispensable for relatively 
normal development (Min et al., 2003). Prior to the availability of selective ligands, blocking 
receptor function was accomplished by introducing into tumor cells a recombinant, truncated 
version of the IGF-Ir with a deleted intracellular tyrosine kinase domain, enabling non-
functional heterodimerization. Genetic blockade via dominant-negative receptor expression 
prevented the formation of sarcomas in nude mice (Prager et al., 1994) and was successful in 
treating lung, colorectal, and pancreatic xenograft models (Min et al., 2003). Since then, a 
number of small-molecule IGF-Ir inhibitors have been discovered, with anti-neoplastic action 
in a wide range of cancers (Carboni et al., 2009; Flanigan et al., 2010; García-Echeverría et al., 
2004; He et al., 2010; Iwasa et al., 2009; Kurio et al., 2011), including several that have now 
moved into clinical trials (Carboni et al., 2009; Iwasa et al., 2009). 
4.3 Genetic pharmacotherapy simulates ligand-mediated restoration of p53 anti-tumor 
activity 
Ventura and colleagues did the study — outside the CNS — that most closely embodies our 
vision of genetic pharmacotherapy (Ventura et al., 2007). They restored function of the 
transcription factor p53, which has tumor suppressor activity, via a global inducible Cre 
strategy. p53 was shown in 1991 to be the most frequently inactivated protein in human 
cancer (Hollstein et al., 1991) so its pathway has been of longstanding interest, and has been 
the subject of molecular therapeutic development efforts (Vassilev, 2004). Pharmacological 
restoration of p53 protein function to achieve tumor regression was achieved indirectly by 
disrupting its interaction with its suppressor protein, MDM2. Indeed, a series of small 
molecules named Nutlins were discovered that are active in the mid-nanomolar range 
(Vassilev, 2004). 
Ventura and colleagues sought to determine whether rescuing p53 function directly would 
induce apoptosis and tumor regression. They made p53-LSL mice in which p53 is knocked 
out due to the insertion of a floxed-Stop (lox-Stop-lox, “LSL”) cassette — which stops 
transcription ahead of the p53 gene — but can be restored by Cre-mediated removal of the 
cassette. These mice were bred with global ROSA26-CreERT2 mice to produce p53 knockout 
mice in which tamoxifen could restore p53 function. After irradiating double mutant 
progeny shortly after birth to accelerate tumor formation, they then showed that tamoxifen 
treatment of the CreERT2-bearing p53-LSL mice resulted in regression of autochthonous 
lymphomas and sarcomas, without affecting normal tissues (Figure 10). 
4.4 Contrasting inducible Cre-lox genetic pharmacotherapy with other modes of 
genetic blockade 
For each of the three targets discussed above for cancer therapy — EGFR, IGF-Ir, and p53 — 
the drug effects mirror those of the genetic pharmacotherapy intervention, corroborating the 
technique’s comparability as a means of testing a pharmacologic proof-of-concept. Although 
the Nutlin molecules increase p53 activity indirectly via MDM2 inhibition, and a genetic 
intervention more directly analogous to the corresponding drug might have targeted a 
floxed-MDM2 allele, the two studies nonetheless demonstrate the anti-tumor effects (proof-
of-concept) of p53-up-regulation (Figure 11). 
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Fig. 10. Genetic pharmacotherapy mediates up-regulation of p53 expression and causes 
regression of autochthonous sarcomas and lymphomas. A. Tamoxifen administration 
caused tumor regression in p53-LSL mice expressing tamoxifen-inducible CreERT2, but not 
in CreERT2-negative p53-LSL mice. B. A series of MRI images (top) shows the regression of 
an abdominal lymphoma (indicated by the white asterisk) after the administration of 
tamoxifen. Below, the tumor volume at the time point of each corresponding MRI image. 
(From: Ventura et al., 2007, with permission) 
 
 
Fig. 11. Parallels in proof-of-concept studies for drug development between ligand-based 
pharmacotherapy and genetic pharmacotherapy, as exemplified by p53 up-regulation for 
cancer pharmacotherapy (Vassilev, 2004; Ventura et al., 2007). Both ligand inhibition of 
MDM2 and tamoxifen-inducible Cre-mediated rescue of homozygous null p53 alleles result 
in an up-regulation of p53 function that halts tumor cell growth and causes apoptosis, 
leading to tumor reduction in mice. 
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While genetically engineering a target for selective inhibition successfully demonstrated the 
proof-of-concept of EGFR knockdown as cancer therapy — as did expression of a dominant-
negative protein to inactivate the endogenous target IGF-Ir — these techniques are highly 
system-specific and impractical for application to systematic target validation. Inducible 
Cre-lox recombination technology, on the other hand, can function as a wild card enabling 
ubiquitous modulation of the target of choice. 
5. Past and current opportunities for genetic pharmacotherapy applications  
A striking example of how genetic pharmacotherapy could have sped up target-validation 
and substantiated drug discovery efforts is illustrated by dopamine D3 receptor ligand 
development for the treatment of schizophrenia. Improved treatments that target novel 
mechanisms implicated in schizophrenia pathophysiology are urgently needed, as current 
therapies provide little if any alleviation for negative symptoms (anhedonia, social 
withdrawal) or cognitive symptoms (working memory, attention processing, cognitive 
flexibility) and furthermore bear a significant side effect profile that contributes to 
dramatically high patient non-adherence (>74%) (Lieberman et al., 2005). In the 1980s, 
studies on propsychotic drugs such as amphetamine showed that the drugs elicit maximal 
dopamine release in the ventral striatum (Di Chiara & Imperato, 1988), whereas 
antipsychotic extrapyramidal side effects (movement disorders) were thought to arise from 
interrupting dopamine release in nigrostriatal connections (Grace & Bunney, 1986). It thus 
became a longstanding pharmacologic goal to block ventral dopaminergic transmission 
selectively while leaving the dorsal nigrostriatal connections implicated in motor control 
unaffected in order to achieve a better side effect profile. So, when cloned in 1990, and seen 
to be distributed just in the ventral striatum (Figure 12), the dopamine D3 receptor 
immediately became a promising drug target for the treatment of schizophrenia (Sokoloff et 
al., 1990). The prediction was that D3 selective antagonists would prove therapeutic with 
reduced motor side effects. 
 
 
Fig. 12. Distribution of dopamine D2 and D3 receptors in coronal sections of the rat brain. 
Autoradiographic visualization of the dopamine D2/D3 receptor ligand [125I] iodosulpride 
binding in a coronal section through the caudate-putamen (CPu) reveals the distribution of 
dopamine D2 receptors (left). While the distribution of dopamine D2 mRNA revealed by 
32P labeled probes (center) matches the iodosulpiride binding, D3 mRNA is localized 
preferentially in the ventral striatum, principally the nucleus accumbens (Acb), the islands 
of Calleja (ICj) and the olfactory tubercle (Tu). (From: Sokoloff et al., 1990, with permission). 
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Although a recently revealed amino acid difference between the highly homologous D2 and 
D3 receptors will provide new guidance for the design of new D3 receptor-selective ligands 
together with resolution of the crystal structure (Chien et al., 2010), sufficiently selective 
ligands are still not available (Lã Ber et al., 2011). Because of the catch-22 that therapeutic 
efficacy of drug targeting cannot be tested until selective ligands are available, and because 
the past two decades have yet to yield a sufficiently selective ligand, the proof-of-concept 
study to demonstrate the therapeutic potential of selective D3 inhibition has yet to be done. 
Inducing D3 knockdown via inducible-Cre technology in mice modeling schizophrenia 
endophenotypes could show whether selective dopamine D3 receptor antagonists would be 
worth pursuing. 
5.1 Genetic pharmacotherapy to test proof-of-concept of glutaminase inhibition 
While all antipsychotic drugs in clinical use currently target the dopamine system, dysfunction 
of glutamatergic synaptic transmission has been repeatedly implicated in the pathophysiology 
of schizophrenia (Javitt, 2010). Schizophrenia appears to involve NMDA-type glutamate 
receptor hypofunction, as phencyclidine (PCP), ketamine and other NMDA receptor 
antagonists induce schizophrenia-like symptoms in normals, exacerbate the condition of 
patients with schizophrenia, and mimic aspects of the disorder in animals (Javitt, 2007; 
Moghaddam, 2003). However, PCP and its congeners paradoxically induce glutamate release, 
and overactivate AMPA/kainate-type glutamate receptors (Moghaddam & Adams, 1998), 
suggesting that tempering release might prove therapeutic. Indeed, mGluR2/3 agonists 
attenuate both PCP-induced glutamate release and PCP-induced motor stimulation in rodents, 
and the mGluR2/3 agonist LY214002 has shown significant promise in early clinical trials 
(Patil et al., 2007). However, therapeutic benefit has yet to be demonstrated in subsequent 
clinical trials, suggesting that other ways of modulating glutamatergic transmission should be 
pursued. One promising target is glutaminase, the mitochondrial enzyme that is the rate-
limiting step in the recycling of neurotransmitter glutamate from glutamine, that is thought to 
catalyze the production of the majority of neurotransmitter glutamate (Kvamme et al., 2001). 
However, there are no known CNS-active glutaminase inhibiters. 
Recent clinical studies identify hyperactivity in hippocampal CA1 as being most associated 
with schizophrenia and predictive in prodromal patients of the transition to diagnosed 
schizophrenia (Schobel et al., 2009). This builds on a growing body of evidence pointing to 
hyperactivity in the hippocampus —presumably due to excessive glutamate transmission — 
as being a primary node in the pathophysiology of the disorder (Lodge & Grace, 2011); 
hippocampal hyperactivity drives dopamine neuron firing leading to excessive dopamine 
release and a positive feedback loop that may drive the transition to schizophrenia (Lisman 
et al., 2010). Interestingly, mice heterozygous for Gls1, the gene encoding glutaminase, 
exhibit a relative hypoactivity in hippocampal CA1 (Gaisler-Salomon et al., 2009)(Figure 13) 
that is the exact inverse of the findings of hyperactivity in hippocampal CA1 in prodromal 
and diagnosed patients with schizophrenia (Schobel et al., 2009). 
Reduced glutaminase expression may therefore confer protection from the pathological 
processes that engender hippocampal hyperactivity in schizophrenia. Glutaminase 
inhibition should temper the upstream driving cause of disease symptomatology, rather 
than block downstream effects such as excessive dopamine release. 
Consistent with the therapeutic potential of glutaminase inhibition, Gls1 heterozygous mice 
showed diminished amphetamine-induced locomotor stimulation and striatal dopamine 
release (Gaisler-Salomon et al., 2009), two animal-model correlates of positive symptoms in 
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schizophrenia. They showed diminished sensitization to amphetamine (Gaisler-Salomon et 
al., unpublished) — sensitization is thought to be a key process involved in the progression 
of schizophrenia (Duncan et al., 1999), and in contrast to patients with schizophrenia, Gls1 
hets showed diminished ketamine-induced frontal cortex activation. The mice showed 
enhanced latent inhibition, a behavioral measure typically diminished in schizophrenia and 
enhanced by administration of antipsychotic drugs (Weiner & Arad, 2009). Other measures 
affected in schizophrenia, including pre-pulse inhibition and working memory, were 
unaffected. Thus, reduction in Gls1 function engendered endophenotypic changes 
suggestive of potential resilience to schizophrenia. Moreover, the global glutaminase 
deficiency seen in Gls1 hets had its strongest impact in the hippocampus, suggesting that 
systemic Gls1 inhibitors should have a similar focal action. Lacking CNS-active glutaminase 
inhibiters, genetic pharmacotherapy offers a way to test the therapeutic potential of 
glutaminase inhibition (Gellman et al., 2011). 
 
 
Fig. 13. Cerebral blood volume (CBV) imaging in the hippocampus of GLs1 het mice.  
The hippocampal formation (a1, a2) is color-coded in an individual CBV map (a3) such that 
warmer colors reflect higher CBV values. Regional CBV is fairly uniform across 
hippocampal subregions in WT mice, but Gls1 het mice show a selective reduction in the 
subiculum and CA1. (From: Gaisler-Salomon et al. (2009), with permission of the authors). 
6. Feasibility and recommendations for systematic use 
For disorders with well-defined molecular targets, genetic pharmacotherapy offers a direct 
way to test the therapeutic potential of inhibiting the target in advance of ligand 
development. The investigator administers tamoxifen to a disease-modeling mouse carrying 
both the global-inducible CreERT2 allele and the floxed version of the targeted allele. The 
resulting DNA recombination event and ensuing change in target expression levels 
simulates pharmacologic target-modulation. The Knockout Mouse Project (www.komp.org) 
(Skarnes et al., 2011) now makes available floxed alleles of genes of interest so that the 
requisite tools are readily or will shortly be available. 
While the Cre-ERT2 approach is most directly applicable to antagonism studies, it can also 
be used for tests of agonism with transgenic mice bearing flox-Stop alleles so that tamoxifen 
administration would turn on an additional allele or alleles; however, such mice are not 
widely available. The tTA-tetO system is similarly useful for studies of agonism, which 
could be most straightforwardly accomplished in transgenic mice bearing the promoter for 
the target gene driving tTA in tandem with tetO driving the target gene. In contrast, 
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antagonism with tTA-tetO, as noted above, is inherently limited by the inability to design 
mutant mice in which the target gene is unperturbed. The utility of these approaches is 
summarized in Table 2. 
In psychiatric disorders such as schizophrenia, molecular targets are less well defined. 
Diagnosis remains symptom-based due to lack of specific biomarkers or objective diagnostic 
tests. Mouse models capture many dimensions of the disorder but cannot be said to be 
models of the disorder (Arguello & Gogos, 2006; Nestler & Hyman, 2010). As such, for 
psychiatric disorders, the search for therapeutics is conducted in two stages. In the first 
stage, recognized behavioral dimensions are evaluated for desired effects of target 
modulation. For schizophrenia, these dimensions include reduction in correlates of positive 
symptoms (Carpenter & Koenig, 2008) and negative symptoms (O'Tuathaigh et al., 2010). In 
the second stage, a mouse model with construct validity — that is, a mouse carrying a 
mutation known to be implicated in the disease state, or that has been exposed to exogenous 
agents known to elicit the disorder — is subjected to the same genetic pharmacotherapy and 
phenomenological assays. Many genetic mouse models have been developed for 
schizophrenia based on genetic mutations that have been associated with the disorder, both 
constitutive (Carpenter & Koenig, 2008) and inducible (Pletnikov, 2009). Models based on 
exogenous agents include in utero challenges (Lodge & Grace, 2009), perinatal lesions (Tseng 
et al., 2009) and drug-induced states (Bickel & Javitt, 2009; Gonzalez-Maeso & Sealfon, 2009). 
 
 CreERT2 tTA-tetO 
Antagonism Ubiquitous CreERT2 :: flox-Target (unperturbed control impossible) 
Agonism Ubiquitous CreERT2:: flox-Stop-Target pTarget-tTA :: tetO-Target 
Table 2. Mouse genetic strategies for genetic pharmacotherapy. Genetic pharmacotherapy 
can mimic pharmacotherapy for both inhibition (target antagonism) or stimulation (target 
agonism). CreERT2 is most practical for inhibition studies as the requisite mouse lines 
(ubiquitous inducible Cre mice, and komp.com-accessible floxed-target mice) are widely 
available. tTA-tetO cannot be used for inhibition as it is impossible to make a doxycycline-
regulatable line without perturbing control expression. Both CreERT2 and tTA-tetO 
strategies are suitable for stimulation studies, limited by the need to make the requisite 
mouse lines. 
7. Conclusions 
The genetic pharmacotherapy strategy enables testing the therapeutic proof-of-concept of 
target modulation in the absence of specific ligands. It allows circumvention of the proof-of-
concept catch-22 in drug development, where the risk of investing in targets with limited 
validation often impedes the pursuit of specific ligands that would eventually be validated. 
It also minimizes the complementary problem of investment in selective ligands that would 
ultimately fail in clinical proof-of-concept studies (Figure 14). The recently announced 
conditional allele library resource (Skarnes et al., 2011) will facilitate efforts to test multiple 
targets with the inducible Cre strategy. Druggable targets that are likely to be disease 
modifying have now been identified (Hajduk et al., 2005; Knox et al., 2011; Zhu et al., 2010). 
The concept and tools of genetic pharmacotherapy have been well established for some 
time, but their potential for systematic application to proof-of-concept evaluation for drug 
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development efforts has not been fully appreciated. Genetic pharmacotherapy should prove 
to be a powerful orthogonal tool (Hardy & Peet, 2004) for drug development.  
The lack of investment in truly innovative psychiatric drugs over the past decades 
underpins the vastly unmet need for better treatments, as the burden of psychiatric illness 
remains high and current treatments remain ineffective or nonexistent (Brundtland, 2001; 
Miller, 2010). Critics of psychiatric drug development argue that because the etiology of 
major mental illnesses remains so poorly understood, adequate treatments cannot be 
developed (Conn & Roth, 2008). However, applying genetic pharmacotherapy in 
increasingly sophisticated mouse models of psychiatric disorders promises to make the full 
mouse genome accessible to drug discovery and so expand greatly the accessibility of 
molecular targets for pharmacotherapies. We believe that this strategy will expedite the 
development of innovative new molecular therapies, particularly for CNS disorders. 
 
 
Fig. 14. Role for genetic pharmacotherapy in early stages of the drug development pipeline. 
Genetic pharmacotherapy (low cost of failure) bypasses ligand development (high cost of 
failure) in enabling target validation; ligand development (tan shading) can then be 
implemented for the most promising targets for which proof-of-concept studies demonstrate 
higher likelihood of success in clinical development (blue shading). 
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